CA2692392A1 - Anti- mcp-1 antibodies, compositions, methods and uses - Google Patents
Anti- mcp-1 antibodies, compositions, methods and uses Download PDFInfo
- Publication number
- CA2692392A1 CA2692392A1 CA002692392A CA2692392A CA2692392A1 CA 2692392 A1 CA2692392 A1 CA 2692392A1 CA 002692392 A CA002692392 A CA 002692392A CA 2692392 A CA2692392 A CA 2692392A CA 2692392 A1 CA2692392 A1 CA 2692392A1
- Authority
- CA
- Canada
- Prior art keywords
- mcp
- antibody
- drug
- human
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims 6
- 239000000203 mixture Substances 0.000 title claims 5
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 title 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 30
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 30
- 239000003814 drug Substances 0.000 claims 23
- 229940079593 drug Drugs 0.000 claims 23
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 4
- 210000003403 autonomic nervous system Anatomy 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 238000000185 intracerebroventricular administration Methods 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 3
- 238000007912 intraperitoneal administration Methods 0.000 claims 3
- 238000007919 intrasynovial administration Methods 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000002924 anti-infective effect Effects 0.000 claims 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 2
- 239000003792 electrolyte Substances 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 claims 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 claims 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000003302 anti-idiotype Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000054751 human RUNX1T1 Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 230000037317 transdermal delivery Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94698807P | 2007-06-29 | 2007-06-29 | |
| US60/946,998 | 2007-06-29 | ||
| PCT/US2008/068696 WO2009006359A2 (en) | 2007-06-29 | 2008-06-30 | Anti- mcp-1 antibodies, compositions, methods and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2692392A1 true CA2692392A1 (en) | 2009-01-08 |
Family
ID=40158715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002692392A Abandoned CA2692392A1 (en) | 2007-06-29 | 2008-06-30 | Anti- mcp-1 antibodies, compositions, methods and uses |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100254992A1 (enExample) |
| EP (1) | EP2170387A4 (enExample) |
| JP (1) | JP2011517548A (enExample) |
| CN (1) | CN101827610A (enExample) |
| AU (1) | AU2008269954A1 (enExample) |
| CA (1) | CA2692392A1 (enExample) |
| IL (1) | IL202996A0 (enExample) |
| WO (1) | WO2009006359A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2686008A1 (en) * | 2011-03-15 | 2014-01-22 | INSERM - Institut National de la Santé et de la Recherche Médicale | Compositions and methods for inhibiting tumor development caused by chemotherapy induced senescence |
| CN110072883A (zh) | 2016-09-28 | 2019-07-30 | 科巴公司 | 治疗性mots-c相关的肽 |
| EP3773627A1 (en) | 2018-03-27 | 2021-02-17 | Cohbar Inc. | Peptide-containing formulations |
| US11739142B2 (en) | 2019-12-18 | 2023-08-29 | Hoffmann-La Roche Inc. | Bispecific anti-CCL2 antibodies |
| CN112358547A (zh) * | 2020-09-30 | 2021-02-12 | 浙江大学 | 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用 |
| AU2022295067A1 (en) * | 2021-06-18 | 2023-12-21 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
| CN118620076B (zh) * | 2024-07-03 | 2024-12-17 | 武汉爱博泰克生物科技有限公司 | 用于检测鼠单核细胞趋化蛋白1的抗体和抗体对及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5510264A (en) * | 1993-09-28 | 1996-04-23 | Insight Biotech Inc. | Antibodies which bind meningitis related homologous antigenic sequences |
| US6696248B1 (en) * | 1995-08-18 | 2004-02-24 | Morphosys Ag | Protein/(poly)peptide libraries |
| JPH0967399A (ja) * | 1995-08-30 | 1997-03-11 | Mitsui Toatsu Chem Inc | 抗ｍｃｐ−１ヒトモノクローナル抗体 |
| PL209786B1 (pl) * | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
| GB0016138D0 (en) * | 2000-06-30 | 2000-08-23 | Novartis Ag | Organic compounds |
| RU2339647C2 (ru) * | 2002-08-19 | 2008-11-27 | Астразенека Аб | Антитела против моноцитарного хемоаттрактантного белка-1 (мср-1) и их применение |
| CA2507080C (en) * | 2002-11-27 | 2015-01-06 | Biogen Idec Ma Inc. | Humanized antibodies against monocyte chemotactic proteins |
| WO2006125201A2 (en) * | 2005-05-19 | 2006-11-23 | Centocor, Inc. | Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses |
| US8114964B2 (en) * | 2005-05-19 | 2012-02-14 | Centocor, Inc. | Anti-MCP-1 antibodies, compositions, methods and uses |
| PE20061444A1 (es) * | 2005-05-19 | 2007-01-15 | Centocor Inc | Anticuerpo anti-mcp-1, composiciones, metodos y usos |
-
2008
- 2008-06-30 AU AU2008269954A patent/AU2008269954A1/en not_active Abandoned
- 2008-06-30 US US12/602,164 patent/US20100254992A1/en not_active Abandoned
- 2008-06-30 EP EP08781142A patent/EP2170387A4/en not_active Withdrawn
- 2008-06-30 CN CN200880105068A patent/CN101827610A/zh active Pending
- 2008-06-30 JP JP2010515209A patent/JP2011517548A/ja active Pending
- 2008-06-30 WO PCT/US2008/068696 patent/WO2009006359A2/en not_active Ceased
- 2008-06-30 CA CA002692392A patent/CA2692392A1/en not_active Abandoned
-
2009
- 2009-12-27 IL IL202996A patent/IL202996A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2170387A2 (en) | 2010-04-07 |
| WO2009006359A2 (en) | 2009-01-08 |
| WO2009006359A8 (en) | 2009-12-30 |
| EP2170387A4 (en) | 2011-01-19 |
| CN101827610A (zh) | 2010-09-08 |
| US20100254992A1 (en) | 2010-10-07 |
| JP2011517548A (ja) | 2011-06-16 |
| IL202996A0 (en) | 2011-08-01 |
| AU2008269954A1 (en) | 2009-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010202813B2 (en) | Anti- MCP-1 antibodies, compositions, methods and uses | |
| US7371825B2 (en) | Anti-MCP-1 antibodies, compositions, methods and uses | |
| US8114964B2 (en) | Anti-MCP-1 antibodies, compositions, methods and uses | |
| EP2182943B1 (en) | Methods and compositions for treating fibrosis related disorders using il-17 antagonists | |
| CA3052095A1 (en) | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis | |
| CA3052578A1 (en) | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis | |
| JP2008546374A5 (enExample) | ||
| CA3133388A1 (en) | Methods for producing anti-tnf antibody compositions | |
| US20100254992A1 (en) | Anti-mcp-1 antibodies, compositions, methods and uses | |
| EP3938391A1 (en) | Methods for producing anti-tnf antibody compositions | |
| CA3133381A1 (en) | Manufacturing methods for producing anti-tnf antibody compositions | |
| WO2006125201A2 (en) | Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses | |
| WO2007146857A2 (en) | Anti- mcp-1 antibodies expressed in lemna, compositions, methods and uses | |
| WO2020152544A1 (en) | Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20130703 |